Insider filing
Traded Apr 7 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 17, 2026 · Filed Mar 20, 2026
A Corcept Therapeutics director paid $813K out of pocket for Corcept Therapeutics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$812,836
Shares × reported transaction price
$500K–$1M
+2.2%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
21 days after results of Feb 24, 2026, 44 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $33.51 on Mar 17, 2026, within 5% of its 52-week low, after an 18% drop over the previous 30 trading days
52-week range $32.15 (Mar 13, 2026) to $114.22 (Mar 31, 2025), 2% of the way up, from 251 adjusted closes. 30 trading days earlier: $40.71 on Feb 2, 2026. Describes the past only, not a forecast
RSI 38, 49% under its 200-day average, 11% under its 50-day average, 71% below the 52-week high, 20-day volatility 63% a year, against the S&P 500: −15 points over 1 month, −60 points over 3 months, −53 points over 6 months
From the adjusted closes up to Mar 17, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any CORT insider since Jun 2021. G Leonard Jr Baker's first purchase of CORT since Jun 2021
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +8.6% | −2.2% | +10.8% |
| 30 days | +33.8% | +9.3% | +24.5% |
| 90 days | +130.7% | +15.1% | +115.5% |
| 180 days | +222.8% | +16.3% | +206.5% |
Past results only. Not a forecast.
Insider filing
Traded Apr 7 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
William Guyer (Chief Development Officer) sold ~$819K of Corcept Therapeutics
Planned saleInsider filing
Traded Apr 7 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.